Adhesion formation after laparoscopic surgery was evaluated in mice of different strains. More adhesions were observed in Swiss, NMRI, and BALB/c mice, with less interanimal variability in BALB/c mice. These data point to genetics effects on adhesion formation, which open new insights in its pathogenesis and indicate the importance of a careful strain selection for animal studies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.fertnstert.2004.11.084 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Low-Modulus Phosphatidylserine-Exposing Microvesicle Alleviates Skin Inflammation via Persistent Blockade of M1 Macrophage Polarization.
Int J Mol Sci
January 2025
Department of Material Science and Engineering, College of Chemistry and Materials Science, Jinan University, Guangzhou 510632, China.
Inflammatory skin diseases comprise a group of skin conditions characterized by damage to skin function due to overactive immune responses. These disorders not only impair the barrier function of the skin but also deteriorate the quality of life and increase the risk of psychiatric issues. Here, a low-modulus phosphatidylserine-exposing microvesicle (deformed PSV, D-PSV) was produced, characterized, and evaluated for its potential therapeutic function against skin diseases.
View Article and Find Full Text PDFThe Role of Fractalkine in Diabetic Retinopathy: Pathophysiology and Clinical Implications.
Int J Mol Sci
January 2025
Department of Ophthalmology, National Taiwan University Hospital, No. 7, Chung Shan S. Rd. (Zhongshan S. Rd.), Zhongzheng Dist., Taipei City 100225, Taiwan.
Diabetic retinopathy (DR) is a complication of diabetes, characterized by progressive microvascular dysfunction that can result in vision loss. Chronic hyperglycemia drives oxidative stress, endothelial dysfunction, and inflammation, leading to retinal damage and complications such as neovascularization. Current treatments, including anti-VEGF agents, have limitations, necessitating the exploration of alternative therapeutic strategies.
View Article and Find Full Text PDFAntimicrobial Activity of Cyclic Lipopeptides and Their Role in the Host Adaptive Response to Changes in Environmental Conditions.
Int J Mol Sci
January 2025
Gause Institute of New Antibiotics, ul. Bolshaya Pirogovskaya, 11, Moscow 119021, Russia.
cyclic lipopeptides (CLP), part of the three main families-surfactins, iturins, and fengycins-are secondary metabolites with a unique chemical structure that includes both peptide and lipid components. Being amphiphilic compounds, CLPs exhibit antimicrobial activity in vitro, damaging the membranes of microorganisms. However, the concentrations of CLPs used in vitro are difficult to achieve in natural conditions.
View Article and Find Full Text PDFCellular Response of Immune Cells in the Upper Respiratory Tract After Treatment with Cold Atmospheric Plasma In Vitro.
Int J Mol Sci
December 2024
Department of Dermatology, University Medical Center Regensburg, 93053 Regensburg, Germany.
Cold atmospheric plasma (CAP) has antimicrobial properties and is also known to stimulate the immune system. These properties could be useful for the development of a novel therapeutic or preventive strategy against respiratory infections in the upper respiratory tract (URT) such as ventilator-associated pneumonia (VAP) without inducing an immune overreaction. This study investigated the cellular responses of polymorphonuclear neutrophils (PMNs) after exposure to CAP in a three-dimensional (3D) model of the URT.
View Article and Find Full Text PDFAntibody-Drug Conjugates in Non-Small Cell Lung Cancer: State of the Art and Future Perspectives.
Int J Mol Sci
December 2024
Department of Oncology, University Hospital of Udine, 33100 Udine, Italy.
Antibody-drug conjugates (ADCs) represent one of the most promising and rapidly emerging anti-cancer therapies because they combine the cytotoxic effect of the conjugate payload and the high selectivity of the monoclonal antibody, which binds a specific membrane antigen expressed by the tumor cells. In non-small cell lung cancer (NSCLC), ADCs are being investigated targeting human epidermal growth factor receptor 2 (), human epidermal growth factor receptor 3 (), trophoblast cell surface antigen 2 (), Mesenchymal-epithelial transition factor (), and carcinoembryonic antigen-related cell adhesion molecule 5 (). To date, Trastuzumab deruxtecan is the only ADC that has been approved by the FDA for the treatment of patients with NSCLC, but several ongoing studies, both using ADCs as monotherapy and combined with other therapies, are investigating the efficacy of new ADCs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!